Yolanda Gilaberte
Yolanda Gilaberte is an expert in Dermatology at Hospital Universitario Miguel Servet (Spain). As of October 2026, ScienceLeadR ranks Yolanda Gilaberte in the top 1% of experts worldwide for Syphilis, Keratosis and Sexually Transmitted Diseases. Yolanda Gilaberte has authored 369 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 4 of them ongoing. SLR score: 1,368 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Public Health - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1993 - 2026
Number : 369
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Trends in meglumine antimoniate prescriptions in Spain (2016-2024): a proxy for cutaneous leishmaniasis burden. PMID 42399604 — meglumine, meglumine antimoniate, leishmaniasis, cutaneous, prescriptions, leishmaniasis, infections | Infection | 2026 | 0 |
| Environmental criteria in dermatology research grants. PMID 42396915 — sexually transmitted diseases, skin diseases, research, environment, dermatology | J Eur Acad Dermatol Venereol | 2026 | 0 |
| "My skin": a public health program for secondary school students in Spain. PMID 42342218 — skin, sexually transmitted diseases, syphilis, schools, public health, dermatology | Actas Dermosifiliogr | 2026 | 0 |
| What's New in Photoprotection? PMID 42260063 — skin, skin diseases, sunscreening agents | Am J Clin Dermatol | 2026 | 0 |
| Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications. PMID 42189399 — skin, sunscreening agents | Dermatol Ther (Heidelb) | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to 12 Years of Age With Severe Alopecia Areata 2024-515438-33-00 — safety, alopecia areata, child, alopecia | Phase 3 | Active not recruiting | 2026 |
| A study to determine the efficacy safety and tolerability of tibulizumab in adults with hidradenitis suppurativa 2024-519736-17-00 — safety, hidradenitis suppurativa, multiple chronic conditions, hidradenitis | Phase 2 | Active not recruiting | 2025 |
| A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata 2024-519370-40-00 — safety, alopecia areata, adolescent, alopecia, non-responder | Phase 3 | Active not recruiting | 2025 |
| Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry NCT05673681 — registries, melanoma, risk factors, dermatology, venereology, prognosis | N/A | Recruiting | 2022 |
LeadR Networks
Main global connection map